Bachem Holding AG/Fr. BANB
1D1W1MYTD1Y5YMAX
Capital at risk
About Bachem Holding AG
Bachem Holding AG is a Swiss company specializing in the biotechnology and pharmaceutical industries. It focuses on the development and production of peptides and oligonucleotides for the pharmaceutical and biotech sectors. Its offerings include active pharmaceutical ingredients (APIs) and customized synthesis services. Founded in 1971, Bachem's headquarters is located in Bubendorf, Switzerland, with additional facilities in the United States, Europe, and Asia. The company is known for its extensive expertise in peptide chemistry and its strategic focus on innovation and quality in manufacturing, contributing to its competitive position in the global pharmaceuticals market.
- Ticker
- Fr. BANB
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 2,725
- Headquarters
- Bubendorf, Switzerland
- Website
- www.bachem.com
BANB Metrics
BasicAdvanced
CHF 5.7B
38.71
CHF 1.98
0.79
CHF 0.90
0.59%
Price and volume
Market cap
CHF 5.7B
Beta
0.79
52-week high
CHF 83.25
52-week low
CHF 48.52
Average daily volume
96K
Dividend rate
CHF 0.90
Financial strength
Current ratio
1.604
Quick ratio
0.456
Long term debt to equity
0
Total debt to equity
0.144
Dividend payout ratio (TTM)
45.30%
Interest coverage (TTM)
149.30%
Profitability
EBITDA (TTM)
210.448
Gross margin (TTM)
27.00%
Net profit margin (TTM)
21.02%
Operating margin (TTM)
21.81%
Effective tax rate (TTM)
5.05%
Revenue per employee (TTM)
CHF 260,000
Management effectiveness
Return on assets (TTM)
4.54%
Return on equity (TTM)
10.63%
Valuation
Price to earnings (TTM)
38.713
Price to revenue (TTM)
8.139
Price to book
3.98
Price to tangible book (TTM)
4.06
Price to free cash flow (TTM)
-99.031
Free cash flow yield (TTM)
-1.01%
Free cash flow per share (TTM)
-0.776
Dividend yield (TTM)
1.17%
Forward dividend yield
0.59%
Growth
Revenue change (TTM)
4.51%
Earnings per share change (TTM)
10.44%
3-year revenue growth (CAGR)
9.70%
10-year revenue growth (CAGR)
12.28%
3-year earnings per share growth (CAGR)
14.51%
10-year earnings per share growth (CAGR)
13.98%
3-year dividend per share growth (CAGR)
6.27%
10-year dividend per share growth (CAGR)
7.18%
Bulls say / Bears say
Bachem brought Building K into operation and is already manufacturing commercial GMP products, supporting its 2026 guidance for 35–40% sales growth in local currencies and an EBITDA margin in the low thirties. (Bachem)
The planned Sisslerfeld facility, targeted to begin production by 2030, could materially expand large-volume peptide and oligonucleotide capacity and support long-term demand growth. (Reuters)
Bachem secured a CHF 500 million five-year revolving credit facility, with a further CHF 150 million increase option, improving financial flexibility to execute its capacity-expansion program. (Reuters)
First-half 2026 EBITDA fell 9.0% year over year and the margin declined to 25.4% from 29.1%, as Building K ramp-up costs weighed on profitability. (Bachem)
Bachem plans CHF 350–400 million of 2026 investment, while the Sisslerfeld project involves more than CHF 500 million and U.S. expansion is expected to require about USD 250 million through 2030; this creates substantial execution, cash-flow and financing risk. (Bachem)
The 2025 EBITDA result benefited from CHF 16.1 million of one-time income, with the adjusted EBITDA margin only 28.6% versus the reported 30.9%; this makes headline profitability and year-over-year comparisons less robust. (Bachem)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Upcoming events
No upcoming events
Funds containing BANB
AllUSDEURGBP
Fund name | Fund size | Fr. BANB weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.31% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.31% |
iShares Healthcare Innovation£DRDR | £1B | 0.31% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.19% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.